Mandibular Ameloblastoma with Lung Metastasis 10 Years after Resection

ABSTRACT

Objective: To present a case of mandibular ameloblastoma with pulmonary metastasis after ten years and discuss the possible pathophysiology, diagnostic and therapeutic options.

Methods:

Design: Case Report

Setting: Tertiary Private Hospital

Patient: One

Results: A 27-year-old woman diagnosed with follicular variant ameloblastoma underwent left segmental mandibulectomy with iliac bone reconstruction in 2004. The titanium plates were removed in 2008 because of a recurrent orocutaneous fistula. She was apparently well until 2014, when she complained of intermittent, non-radiating, sharp and piercing, right upper back pains. Work-ups revealed multiple bilateral lung nodules. A CT scan-guided percutaneous needle biopsy of the right upper lung nodule revealed metastatic ameloblastoma. Opting for observation instead of chemoradiation, she remains asymptomatic on regular follow-ups with medical oncology, pulmonary medicine and otorhinolaryngology.

Conclusion: Though benign, ameloblastoma has a high propensity for local invasion and may metastasize. It is difficult to predict metastasis, even with adequate treatment of the primary lesion. There is no standard protocol to prevent or detect metastatic ameloblastoma, but regular and close follow up may ensure early diagnosis.

Keywords: ameloblastoma, metastatic ameloblastoma, lung metastasis, follicular type ameloblastoma, odontogenic tumor
frequently, the skull, liver, parotid gland, diaphragm, and brain. We present a case of a mandibular ameloblastoma with lung metastasis and discuss the possible pathophysiology, diagnostic and therapeutic options.

CASE REPORT

A 27-year-old woman with no known co-morbidities consulted in 2004 for a gradually enlarging left mandibular mass since 2002. Wedge biopsy revealed ameloblastoma and a segmental mandibulectomy with iliac bone reconstruction was performed that same year. The final histopathology revealed ameloblastoma, follicular variant. A post-operative orocutaneous fistula was repaired twice, in November and December 2004. She remained apparently well (with normal routine annual chest x-rays) on regular follow-ups until 2008, when the fistula recurred. The titanium plates and screws were removed, and the fistula was repaired. Her condition allegedly improved and she was lost to follow-up thereafter.

She was reportedly well until 2014, 10 years after the first surgery, when she noted intermittent, non-radiating, sharp and piercing, right upper back pains with no associated symptoms. Bilateral multiple pulmonary nodules were seen on chest X-Rays. Her otorhinolaryngologic and chest examinations were unremarkable with symmetrical chest expansion, no lag, and clear, equal breath sounds. Considering an infectious process versus metastasis from a primary neoplasm, a high resolution chest CT scan with contrast showed “multiple varied-sized, non-calcified, non-enhancing pulmonary and pleural-based nodules/masses in both lungs.” The largest on the right was located in the anterior basal segment of the right lower lobe measuring approximately 2.2 x 3.3 cm. (Figure 1) The findings were compatible with metastases.

A CT scan-guided percutaneous needle biopsy of right upper lung nodule yielded “highly cellular smears with spindle cells, scattered singly and in tight and loose clusters admixed with atypical epithelial cells, set in a bloody background,” (Figure 2) with chondromyxoid stroma in some clusters. The cell block showed “stellate reticulum-like cells in clusters with peripheral palisading columnar cells, some exhibiting reverse polarization.” (Figure 3) Final histopathology results were signed out as “cytomorphologic findings consistent with metastatic ameloblastoma.”

Plain CT scans revealed no recurrence of the osseous tumor in the left mandibular body. (Figure 4) She was given oral analgesics for the back pain, and offered chemotherapy and radiotherapy. She opted to observe her condition with regular monitoring instead, since she was then asymptomatic. She is currently well and is being monitored by medical oncology, pulmonary medicine and otorhinolaryngology.
CASE REPORTS

primary and metastatic tissues demonstrating benign histological features; whereas an ameloblastic carcinoma exhibits malignant features, such as cellular atypia and mitosis. Metastatic ameloblastoma is rare with about 70 reported cases. Both the gnathic primary tumor and the metastatic foci have typical morphologies of a benign ameloblastoma with bland nuclei and absent to rare mitosis. This histopathologic features of metastatic ameloblastoma are consistent with our case, although atypical epithelial cells were noted, this is a focal type of atypia which can sometimes also be seen in benign cases.

There is no definite pathophysiologic basis for how ameloblastoma can metastasize, but three routes are mentioned in the literature: hematogenous, lymphatic, and by aspiration. Another possible mode of metastasis is tumor implantation during surgical procedures. Other studies theorized that multiple surgeries can significantly increase the risk of metastases, and that curettage opens pathways for dissemination of the tumor to adjacent structures, which may lead to surgical seeding. In our case, metastasis could have been due to two routes: first, hematogenous since the tumor was diffusely scattered in both lung fields; and second by aspiration from the endotracheal tube during her previous surgery. Because the exact mechanism of metastasis remains unknown, only speculations can be made.

We are not aware of any report on the specific signs and symptoms
of metastatic ameloblastoma, and most cases of ameloblastoma are asymptomatic. In this case, our patient only presented with an intermittent, non-radiating, sharp and piercing, right upper back pains. Diagnosis is usually due to incidental findings on CT scan or chest x-ray, which prompts further work-up. The diagnosis of metastatic ameloblastoma can only be made in retrospect; hence, it is difficult to predict which cases would metastasize and which would not. There may be a role for routine annual chest x-rays (which in our patient’s case were a social service requirement), but as also seen in our case, were negative for five years.

The prognosis of metastatic ameloblastoma is poor. Henderson et al. reported a median survival of approximately 2 years after the detection of metastasis. The mean survival of patients who did not receive any treatment or who were treated with multi-agent chemotherapy was 1.1 years. Another study that reviewed 29 cases of ameloblastoma with lung metastases concluded that median survival was longer at around 6.6 years when surgical resection was performed compared to other treatment modalities or close monitoring.

Because of the rarity of metastatic ameloblastoma, the clinical course and appropriate treatment are not yet established. Close observation, surgical resection, and chemotherapy/radiotherapy are treatment options. Adequate treatment of the primary lesion is the most important element in the management of ameloblastoma.

For isolated and discrete lung metastatic ameloblastoma, particularly in the lung periphery, treatment may be via open thoracotomy and wedge resection, or by lobotomy, depending on the number of lesions and their location. Significant resection, with preservation of as much viable lung tissue as possible, is the treatment of choice. Surgical resection was not an option for our patient since multiple nodules were noted in both lungs, as it is best considered if the lesion is solitary and peripherally located.

Other treatment modalities, such as chemotherapy and radiotherapy, are yet to be defined. Chemotherapy has shown variable results, in some cases achieving only a reduction in tumor size, but producing no effective improvement in most cases. Currently there is no single-agent or combination chemotherapy regimen that can be recommended for palliation in patients with unresectable metastases. However, there are some reports showing metastatic ameloblastoma to the lungs that responded well to carboplatin/paclitaxel, suggesting benefits for systemic treatment in cases with inoperable disease. Radiotherapy has been recommended for inoperable metastatic deposits, but because the response is unpredictable, it should be used only for palliative care. Because the tumor is unresectable and the patient has no signs of disease progression, her choice to forego chemoradiation in favor of close monitoring and symptomatic relief of symptoms is the best treatment option at the moment.

Though benign, ameloblastoma has a high propensity for local invasion and may rarely metastasize, most commonly to the lungs. It is difficult to predict metastasis, even with adequate treatment of the primary lesion, as there is no sign or symptom specific for metastatic ameloblastoma. There is no standard protocol to prevent or detect metastatic ameloblastoma, but regular and close follow up and monitoring, even years after primary resection, may ensure early diagnosis.

REFERENCES